Quantcast

Company Updates, Takeover Offers, Stock Price Movements, and FDA Approvals – Analyst Notes on Chubb, Valeant, AstraZeneca, Mylan and Perrigo

May 20, 2014

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, May 20, 2014 /PRNewswire/ –

Today, Analysts Review released its analysts’ notes regarding The Chubb Corporation
(NYSE: CB), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), AstraZeneca Plc
(NYSE: AZN), Mylan, Inc. (NASDAQ: MYL) and Perrigo Co. (NYSE: PRGO). Private wealth
members receive these notes ahead of publication. To reserve complementary membership,
limited openings are available at: http://www.analystsreview.com/2680-100free.


The Chubb Corporation Analyst Notes
On May 15, 2014, The Chubb Corporation (Chubb) announced that it has created the Fine Art
Practice at Chubb, assimilating its expertise of fine art resources in underwriting, loss
prevention, appraisal and claims to respond to the ever-changing needs of its personal
insurance clients. Melissa Lalka, Vice President and Worldwide Fine Art Manager for Chubb
Personal Insurance, has been nominated to spearhead the project. Melissa Lalka, quoted,
“By being able to connect with some of the world’s leading authorities on art, we are able
to settle some very complex claims fairly and efficiently. In some cases, it involves
assisting in the restoration of a great work so it may be enjoyed by future generations,
rather than simply paying for a loss.” The Fine Art Practice has access to Chubb’s global
fine art resources, including 20 fine art and collector specialists in the U.S., as well
as underwriting and claims professionals. The full analyst notes on Chubb are available to
download free of charge at:

http://www.analystsreview.com/2680-CB-20May2014.pdf


Valeant Pharmaceuticals International, Inc. Analyst Notes
On May 13, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) issued a press
release responding to Allergan, Inc.’s decision to reject Valeant’s proposal to combine
with Allergan for $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan
share. Valeant stated that it will hold a webcast on May 28, 2014 at 8:00 a.m. ET/5:00
a.m. PT to discuss the advantages of their prosed offer. During the call, Valeant will
also provide further details about its operating model, business strategy, and transaction
cost synergies, and said that it plans to improve its offer for Allergan. Lastly, Valeant
stated that it remains excited about the opportunity for value creation for all
shareholders from the strategic and financial synergies resulting from this transaction.
The full analyst notes on Valeant are available to download free of charge
at:http://www.analystsreview.com/2680-VRX-20May2014.pdf


AstraZeneca Plc Analyst Notes
On May 15, 2014, stock of AstraZeneca PLC (AstraZeneca) closed at $80.52, up 2.85%.
However, the broader market index (NYSE Composite), fell 0.82% to settle at 10,568.37. The
stock opened at $78.67 and oscillated in the range $78.47 – $80.62 during the trading
session. A total of 6.51 million shares traded during the day, higher than the previous
day trading volume of 5.49 million shares and the 30-day average trading volume of 5.93
million shares. The shares are trading near their 52-week high of $82.68, which it made on
May 1, 2014, when AstraZeneca rejected a takeover bid from Pfizer for the third time. The
full analyst notes on AstraZeneca are available to download free of charge
at:http://www.analystsreview.com/2680-AZN-20May2014.pdf


Mylan, Inc. Analyst Notes
On May 15, 2014, Mylan Inc. (Mylan) commented on the ruling by the U.S. District Court for
the District of Columbia against Teva in their suit against the U.S. Food and Drug
Administration (FDA), denying Teva’s motion to block FDA from approving generic versions
of Copaxone and dismissed the case for lack of jurisdiction. Heather Bresch, CEO, Mylan,
quoted, “Teva’s suit against FDA was simply a desperate, last minute tactic, among others,
to delay access to more affordable generic versions of Copaxone(R) for patients in the
U.S. Following the Court’s decision against Teva, we continue to see no barrier to FDA
approval of Mylan’s generic Copaxone following patent expiry, and we look forward to being
able to launch this very important first generic product for multiple sclerosis at market
formation.” The full analyst notes on Mylan are available to download free of charge
at:http://www.analystsreview.com/2680-MYL-20May2014.pdf


PerrigoCo.AnalystNotes
On May 12, 2014, Perrigo Company Plc (Perrigo) announced its receipt of final approval
from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA)
for azelastine hydrochloride nasal spray (0.15%). According to Perrigo, Astepro Nasal
Spray is a prescription medicine for people aged 12 years and above and is approved to
treat nasal symptoms caused due to seasonal allergies or environmental irritants. The
Company informed that ANDA involved contributions from both Perrigo and Impax
Laboratories, Inc., who will share costs and benefits of the product. Perrigo stated that
it has started to ship the product to its customers. The Company stated that as measured
by Symphony Health Solutions, annual sales of Astepro Nasal Spray were approximately $97
million. The full analyst notes on Perrigo are available to download free of charge
at:http://www.analystsreview.com/2680-PRGO-20May2014.pdf


About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive
membership. We are constantly hiring researchers, writers, editors and analysts to add to
our team and become better than yesterday. If being a part of a fast growing community
with an edge in today’s market sounds interesting to you, then sign-up today and
experience the full benefits of membership. ===============
EDITOR’S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the
companies mentioned. 2. Information in this release is produced on a best efforts basis by
Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by
an outsourced research provider. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us below. 3. This
information is submitted as a net-positive to companies mentioned, to increase awareness
for mentioned companies to our subscriber base and the investing public. 4. If you wish to
have your company covered in more detail by our team, or wish to learn more about our
services, please contact us at pubco [at] http://www.analystsreview.com 5. For any
urgent concerns or inquiries, please contact us at compliance [at]
http://www.analystsreview.com 6. Are you a public company? Would you like to see
similar coverage on your company? Send us a full investors’ package to research [at]
http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article
or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An
outsourced research services provider has only reviewed the information provided by
Analysts Review in this article or report according to the procedures outlined by Analysts
Review. Analysts Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports, as the case
may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the information
provided in this document. This information is not to be construed as personal financial
advice. Readers are encouraged to consult their personal financial advisor before making
any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of
printing of this document or any error, mistake or shortcoming. No liability is accepted
by Analysts Review whatsoever for any direct, indirect or consequential loss arising from
the use of this document. Analysts Review expressly disclaims any fiduciary responsibility
or liability for any consequences, financial or otherwise arising from any reliance placed
on the information in this document. Analysts Review does not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information, or (2) warrant any
results from use of the information. The included information is subject to change without
notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA
Institute.

SOURCE Analysts Review


Source: PR Newswire



comments powered by Disqus